Shares of Neurocrine Biosciences Inc. surged in Tuesday’s extended session after the biotechnology company said it received Food and Drug Administration approval for Ingrezza to treat tardive dyskinesia, a neurological disorder. Ingrezza “is the first and only FDA-approved product indicated for the treatment of adults with TD,” said the company in a statement. Neurocrine shares jumped 13% after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News